Benelux Vagus Nerve Stimulation Devices Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

Uptick in Drug-Resistant Neurological Conditions Worldwide

The Benelux vagus nerve stimulation (VNS) devices market is influenced by a steady rise in drug-resistant neurological conditions, particularly epilepsy and complex mood disorders, within highly developed healthcare systems such as Belgium, the Netherlands, and Luxembourg. Despite strong pharmaceutical access and advanced neurological care pathways, a subset of patients continues to exhibit resistance to multi-line anti-epileptic therapies, creating a niche but clinically significant demand for neuromodulation-based interventions.

For example, the epilepsy cases that need a high level of intervention have started being managed through centralized treatment centers for epilepsy, including academic hospitals located in Utrecht and Amsterdam in the Netherlands. Belgium, being a country with a multilingual healthcare system, has established specialized neurology networks, within which epilepsy cases that are difficult to treat are referred to tertiary neurocare centers. Similarly, in Luxembourg, the small number of patients makes cross-border treatment possible due to neighboring countries.

Moreover, neurological problems occurring due to stroke in aging populations in the Benelux region are leading to an increasing number of patients with secondary epilepsy and other neurofunctional disabilities. With one of the fastest-growing populations in Western Europe, the region is experiencing a steady increase in patients with neurological disorders that cannot be adequately managed using conventional pharmaceutical methods. This is fueling research into alternative treatments like VNS.

Moving into New Therapeutic Indication Fields

In the Benelux countries, the use of vagal nerve stimulation technology is slowly gaining popularity from applications in epilepsy to other fields such as psychiatry and neurorehabilitation, thanks to robust clinical research facilities and collaborations among researchers across borders. Hospitals in the Netherlands and Belgium have been involved in the development of neuromodulation technologies used to address depression resistant to medication and psychotherapy.

Another area attracting attention in recent years is stroke rehabilitation, where there is an increasing focus by clinicians on the role of VNS in promoting neuroplasticity and recovery in patients after stroke. This is evident from several ongoing research efforts involving the integration of various approaches, such as physical and occupational therapy, within Dutch centers for neurorehabilitation.

In addition, chronic migraine and autonomic nervous system disorders are gaining attention in Benelux pain management clinics, where there is increasing openness to non-pharmacological treatment options. Luxembourg‘s cross-border patient access model also enables exposure to experimental neuromodulation therapies through collaborations with Belgian and German medical centers. This interconnected healthcare ecosystem is supporting gradual but steady diversification of VNS applications beyond traditional neurological indications.

The "Benelux Vagus Nerve Stimulation Devices Market Size and Forecast (2022-2033)" report provides a detailed analysis of the market covering below areas:

• Market size and forecast at regional and country levels for all market segments covered under the scope
• Market trends, as well as drivers, restraints, and opportunities
• Market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Market concentration, heat map analysis, prominent players, and recent developments for the Market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Benelux Vagus Nerve Stimulation Devices market report is divided into: Belgium, the Netherlands, and Luxembourg. The Netherlands held the largest share in 2025.

The Netherlands holds dominance in the use of VNS Devices in the Benelux region owing to the highly developed neurological care sector and an emphasis on evidence-based adoption of medical equipment in the country. The key players behind device adoption in the Netherlands include the Dutch Epilepsy Centers and University Hospitals. The reason for this includes the fact that VNS Device use is more predominant among those suffering from refractory epilepsy that cannot be managed using anti-seizure drugs.

One of the major strengths of the Netherlands market is that there is significant participation from hospitals in multiple-center studies of neuromodulation results. This helps enhance confidence among physicians and allows for slow expansion of the indication for use. Furthermore, having competent neurosurgeons and neurologists who have knowledge about neurostimulation implantable devices will help achieve consistency in treatment and reduce any adverse risks during procedures. The reimbursement landscape in the Netherlands market is quite encouraging, where there is proof of necessity. However, there is no widespread uptake outside large academic and tertiary hospitals owing to the need for central expertise. Nonetheless, the Netherlands market plays a key role as the main source of innovation and uptake of VNS devices in the Benelux countries, including Belgium and Luxembourg.

• The report includes qualitative and quantitative data in the Benelux Vagus Nerve Stimulation Devices market across product type, type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Benelux Vagus Nerve Stimulation Devices market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Benelux Vagus Nerve Stimulation Devices market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Benelux Vagus Nerve Stimulation Devices market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover the Benelux Vagus Nerve Stimulation Devices market segments by product type, type, application, end user, and geography across Belgium, the Netherlands, and Luxembourg. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Benelux Vagus Nerve Stimulation Devices market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The Benelux Vagus Nerve Stimulation Devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Benelux Vagus Nerve Stimulation Devices market are:

• In December 2024, LivaNova PLC announced that new clinical outcomes from the RECOVER study of its Vagus Nerve Stimulation Therapy system were published, demonstrating clinically meaningful improvements in treatment-resistant depression, supporting broader clinical adoption of VNS Therapy in Europe, including Belgium, the Netherlands, and Luxembourg under established CE-mark indications.
• In February 2023, LivaNova PLC announced that it launched SenTiva DUO, a next-generation implantable vagus nerve stimulation pulse generator, strengthening its VNS Therapy portfolio for drug-resistant epilepsy and enabling upgrades for existing implanted patients in European markets, including Benelux countries under CE-mark coverage.